Prl-3 is an oncogenic driver in triple-negative breast cancers and a mediator of the novel anticancer compound AMPI-109
Triple-negative breast cancers (TNBCs) are among the most aggressive and heterogeneous cancers characterized by a high propensity to invade, metastasize and relapse. AMPI-109 is a novel anticancer compound that is selectively efficacious in inhibiting proliferation and in inducing apoptosis of multiple TNBC subtype cell lines as assessed by activation of pro-apoptotic caspases-3 and 7, PARP cleavage and nucleosomal DNA fragmentation. Because AMPI-109 has little to no effect on growth in the majority of non- TNBC cell lines, we utilized AMPI-109 in a genome-wide shRNA screen to investigate the ...
(For more, see "View full record.")